摘要:
The present invention relates to gastroresistant and enterosoluble microparticulate systems for the encapsulation of biologically active substances selected from: flavonoids, vitamins, antioxidants, immunostimulants, starchy and non-starchy polysaccharides, probiotics, prebiotics, intestinal trophism regulators, oligoelements, enzymes and bioactive peptides. Such microparticulate systems allow the administration of the aforementioned nutraceutic substances to animals such as porcines, bovines, caprines, ovines, equids, canids, felines, camelids, lagomorphs, rodents, fowl, and other mammals, including humans, fish and crustaceans, increasing the bioavailability.
摘要:
Novel melatonin ligands of Formula (I) or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8;Y is selected from the group consisting of hydrogen, aryl, heteroaryl, CrC6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, -OCF3, CF3, C1-C8 alkyl, C1C8 alkyloxy, C1C8 alkylthio, halogen and -Z-(CH2)P-A; R1 is selected from the group consisting of C1C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1C4 alkyl, hydroxy-substituted C3-C6 cycloalkyl, and NHR5, wherein R5 is C1C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an -0-(CH2)v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system; R4 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R6 is selected from the group consisting of hydrogen and C1C6 alkyl; R7 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; and R8 is selected from the group consisting of hydrogen and C1C4 alkyl.
摘要:
A method for planning crop rotations in at least one plot (h i , i=1...n) of land within a predetermined planning horizon or time (T), to implement a cropping method, includes the steps of: for said or each plot (h), determination of a set (C) of acceptable crops (c) based on the soil nature of the plot(s) (h), an availability of irrigation, exposure, and geographic coordinates; for said or each plot (h), definition of a succession of planting periods (t) until the planning horizon (T) is completed; specification of a plurality of desired crops (c i ) among the acceptable crops; choice of a σ sequence of k crops, where k≥2, among the desired crops (c i , i=1...k); definition of a plurality of eligible sequences σ of the desired crops c i to be assigned to plot h, according to respective predetermined time orders, subject to agronomic constraints including on each plot, uniqueness of the crop c to be assigned in each planting period t, and minimum and maximum area assigned to each crop c in each planting period t; determination, for each of the eligible sequences σ, and for all p sowing periods t of planning time T, of a total yield π h for said or each plot h, obtained as the sum of seasonal yields Y h in sowing periods t, in which each of the seasonal yields in a sowing period t is calculated based on a maximum number of crops k comprising the assigned crop in sowing period t, and the k-1 assigned crops, according to each of the sequences, in a corresponding k-1 number of consecutively preceding earlier sowing periods preceding said sowing period (Figure 1).
摘要:
Object of the present invention is the use of selective agonists of beta-adrenergic type 3 receptors (BAR3) in the treatment of nephrogenic diabetes insipidus (NDI), in particular of X-linked nephrogenic diabetes insipidus (X-NDI).
摘要:
The present invention refers to isoxazole derivatives, in particular 3,4-diaryl isoxazole derivatives, to their pharmaceutical compositions, the process for preparing them and their use as inhibitors of cycloosygenase, in particular of cycloosygenase 1 and 2 (COX-1) (COX-2). The present invention also refers to a process for determining the potential toxicity of compounds that inhibit cycloosygenase (COX), in particular cycloosygenase-2 (COX-2) isoform, and to the use of compounds that inhibit cycloosygenase (COX), in particular cycloosygenase-2 (COX-2) and their pharmaceutical compositions, in subjects for whom the potential cardiovascular toxicity of said compounds is reduced.
摘要:
The present invention relates to a histaminase of vegetable origin to be used in the treatment of allergic and septic shock and inallergic asthma. The invention also regards the preparation of the histaminase for pharmaceutical use and the corresponding pharmaceutical compositions.